A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
Status:
Completed
Trial end date:
2017-03-22
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate that low risk Pulmonary Embolism (PE) participants
who are discharged from the Emergency Department (ED) to the home environment and treated
with rivaroxaban as outpatients have fewer total days in the hospital for bleeding and/or
venous thromboembolism (VTE) events through Day 30 compared to participants who are treated
with initial hospitalization and standard-of-care.